Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 10/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7531577 | 0.88 | CACNA1B (0.51) | CACNA1BEPHX2CASR | |
| SCHEMBL6927489 | 0.85 | CACNA1B (0.53) | CACNA1BEPHX2 | |
| SCHEMBL4495941 | 0.82 | CACNA1B (0.69) | CACNA1BEPHX2CASR | |
| SCHEMBL6930278 | 0.80 | CACNA1B (0.49) | CACNA1BEPHX2KCNA5 | |
| SCHEMBL6931175 | 0.77 | CACNA1B (0.51) | CACNA1BEPHX2 | |
| SCHEMBL6931116 | 0.75 | CACNA1B (0.58) | CACNA1BCASR | |
| SCHEMBL4502482 | 0.75 | CACNA1B (0.59) | CACNA1B | |
| SCHEMBL4510068 | 0.75 | CACNA1B (0.59) | CACNA1BCASR | |
| SCHEMBL7527590 | 0.75 | CACNA1B (0.68) | CACNA1B | |
| SCHEMBL6929492 | 0.72 | CACNA1B (0.55) | CACNA1BCASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610717-B2 | Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease | AJINOMOTO CO., INC. (JP) | 2003-08-26 | — | — | US | disclosed |
| US-6610717-B2 | Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease | AJINOMOTO CO., INC. (JP) | 2003-08-26 | — | — | US | disclosed |